This proposal is for continuation of research into the natural history, treatment and epidemiology and of the statistical conduct, design, collation and publication of childhood cancer. It continues to emphasize the multimodal treatment aspects of the CCSG. Long term survival in all childhood malignancies regardless of diagnosis or age has now reached 50%. By research into the biology of these diseases and careful stratification by patient and tumor cell markers, treatment of all diseases has been broken down into many aspects. In this manner, certain groups of patients with acute lymphocytic leukemia have reached an 80% long term survival rate with minimal therapy. In non-Hodgkins lymphoma, Wilms tumor and rhabdomyosarcoma select groups have reached a 90- 95% disease free survival. Research into brain tumors has been ongoing for the past 5-8 years and multimodal therapy is now showing results of over 50%, which is also being seen in osteogenic sarcoma. The present proposal will accomplish further definition of these diseases and will look for ever better treatment results with less toxicity. In cooperation with the pediatric oncology group, important protocols have been designed or are about to be undertaken in hepatomas, Ewings sarcoma and certain types of brain tumors. In the period December 1982 through November 1987, this institution has seen a total of 689 patients with malignant disease, 424 of these were entered on CCSG studies. Professional personnel at CHMC are very active in CCSG activities. Dr. Chard, Principal Investigator, has been Associate Chairman for Leukemia studies and Vice Chairman of CCSG in he past and is presently Vice Chairman of studies for Acute Non-lymphocytic Leukemia. Dr. Bleyer is Associate Chairman for leukemia, Non-Hodgkins Lymphoma and New Agents. Dr. Bernstein is Chairman of the Immunology Committee, Dr. Pendergrass is a member of the Epidemiology Strategy Group. Dr. milstein, neurologist and Dr. Berger, neurosurgeon, are also members of brain tumor studies. Dr. Schaller, general surgeon, is a member of a number of surgical committees. CHMC in cooperation with the Fred Hutchinson Cancer Research Center is a major contributor to CCSG bone marrow transplantation studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA010382-23
Application #
3555922
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1976-12-01
Project End
1993-11-30
Budget Start
1988-12-01
Budget End
1989-11-30
Support Year
23
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98105
Geyer, J Russell; Sposto, Richard; Jennings, Mark et al. (2005) Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23:7621-31
Neudorf, Steven; Sanders, Jean; Kobrinsky, Nathan et al. (2004) Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103:3655-61
Dudkin, Vadim Y; Miller, Justin S; Danishefsky, Samuel J (2004) Chemical synthesis of normal and transformed PSA glycopeptides. J Am Chem Soc 126:736-8
Sievers, Eric L; Lange, Beverly J; Alonzo, Todd A et al. (2003) Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 101:3398-406
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33

Showing the most recent 10 out of 25 publications